{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.9","upperLimit":"95.5","value":"84.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Complete cytogenetic response (CCyR) - 0% Ph+ metaphases No response - \\>95 to 100% Ph+ metaphases","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"up to 66 cycles","title":"Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}